Page last updated: 2024-11-04

vorinostat and Retinal Degeneration

vorinostat has been researched along with Retinal Degeneration in 1 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Retinal Degeneration: A retrogressive pathological change in the retina, focal or generalized, caused by genetic defects, inflammation, trauma, vascular disease, or aging. Degeneration affecting predominantly the macula lutea of the retina is MACULAR DEGENERATION. (Newell, Ophthalmology: Principles and Concepts, 7th ed, p304)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Dong, Y1
Yan, J1
Yang, M1
Xu, W1
Hu, Z1
Paquet-Durand, F1
Jiao, K1

Other Studies

1 other study available for vorinostat and Retinal Degeneration

ArticleYear
Inherited Retinal Degeneration: Towards the Development of a Combination Therapy Targeting Histone Deacetylase, Poly (ADP-Ribose) Polymerase, and Calpain.
    Biomolecules, 2023, 03-23, Volume: 13, Issue:4

    Topics: Animals; Calpain; Histone Deacetylases; Mice; Photoreceptor Cells, Vertebrate; Poly(ADP-ribose) Poly

2023